Get started
Author

Katarina Niward

Observed names: K Niward, K. Niward, Katarina F Niward, Niward Katarina, Niward, Katarina
ORCID: 0000-0002-5290-5165
Observed ORCID: 0000-0002-5290-5165
OpenAlex ID: A5024502790
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
2021 · The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Pere Domingo, et al. · JAMA · 678
Two-year follow-up of patients with post-COVID-19 condition in Sweden: a prospective cohort study
2023 · Carl Wahlgren, Gustaf Forsberg, et al. · The Lancet Regional Health - Europe · 102
Cognitive dysfunction in post‐COVID‐19 condition: Mechanisms, management, and rehabilitation
2023 · Marika Möller, Kristian Borg, et al. · Journal of Internal Medicine · 84
PDF
Rehabilitation needs following COVID-19: Five-month post-discharge clinical follow-up of individuals with concerning self-reported symptoms
2021 · Carl Wahlgren, Anestis Divanoglou, et al. · EClinicalMedicine · 61
PDF
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
2021 · Karin Welén, Ebba Rosendal, et al. · European Urology · 54
PDF
Development and validation of a simple LC-MS/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma
2020 · Xubin Zheng, Erwin M. Jongedijk, et al. · Journal of Chromatography B · 34
PDF
Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting
2018 · Katarina Niward, Lina Davies Forsman, et al. · Journal of Antimicrobial Chemotherapy · 21
PDF
Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients
2023 · Ge Shao, Ziwei Bao, et al. · Frontiers in Pharmacology · 20
PDF
Individualised dosing algorithm and personalised treatment of high‐dose rifampicin for tuberculosis
2019 · Robin J. Svensson, Katarina Niward, et al. · British Journal of Clinical Pharmacology · 20
PDF
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China
2020 · Lina Davies Forsman, Katarina Niward, et al. · European Respiratory Journal · 16
PDF
Sedimentation rate and suPAR in relation to disease activity and mortality in patients with tuberculosis
2019 · H. Schulman, K. Niward, et al. · The International Journal of Tuberculosis and Lung Disease · 15
Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis
2023 · Haoyue Zhang, Yuying He, et al. · Frontiers in Pharmacology · 14
PDF
Susceptibility testing breakpoints forMycobacterium tuberculosiscategorize isolates with resistance mutations ingyrAas susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB
2015 · Katarina Niward, Kristian Ängeby, et al. · Journal of Antimicrobial Chemotherapy · 14
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial
2023 · Jonas Sundén-Cullberg, Puran Chen, et al. · PLoS ONE · 10
PDF
Second-line antituberculosis drug exposure thresholds predictive of adverse events in multidrug-resistant tuberculosis treatment
2024 · Sainan Wang, Lina Davies Forsman, et al. · International Journal of Infectious Diseases · 9
PDF
COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial
2021 · Karin Welén, Anna K Överby, et al. · Trials · 9
PDF
Extrapulmonary Tuberculosis
2021 · Judith Bruchfeld, Lina Davies Forsman, et al. · Springer eBooks · 9
Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study
2018 · Lina Davies Forsman, Katarina Niward, et al. · BMJ Open · 9
PDF
Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens
2023 · Yue Zhu, Limei Zhu, et al. · Antimicrobial Agents and Chemotherapy · 8
PDF
Risk factors for ventilator‐associated lower respiratory tract infection in COVID ‐19, a retrospective multicenter cohort study in Sweden
2023 · Gustaf Forsberg, Knut Taxbro, et al. · Acta Anaesthesiologica Scandinavica · 7
Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report
2022 · Katarina Nyström, Maria Hjorth, et al. · BMC Infectious Diseases · 7
PDF
Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)
2022 · David Ekqvist, Anna Bornefall, et al. · BMJ Open · 6
PDF
Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay
2018 · Katarina Niward, Linnea Ek Blom, et al. · Antimicrobial Agents and Chemotherapy · 4
PDF
Future Prospects for Using Clinical Phenotypes in Tuberculosis Precision Medicine—An Approach for Clinical Management
2025 · Katarina Niward, Clara Braian, et al. · Clinical Infectious Diseases · 3
Improved 60‐day survival but impaired general health in Swedish ICU‐COVID patients: An ambidirectional population‐based study
2022 · Gustaf Forsberg, Sören Berg, et al. · Acta Anaesthesiologica Scandinavica · 3
Works count: 36
Citation count: 1,219
H-index: 13
I10-index: 14
Year
Topic
Type